JIN Yang Pharmaceutical진양제약
007370 · KOSDAQ · ₩007370 · 진양제약
₩3,405▼ ₩50 (1.45%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩121B | ₩113B | ₩94B | ₩76B | ₩63B |
| Cost of sales | ₩43B | ₩43B | ₩37B | ₩31B | ₩29B |
| Gross profit | ₩78B | ₩70B | ₩57B | ₩46B | ₩34B |
| Operating income | ₩2.5B | ₩12B | ₩9.1B | ₩11B | ₩7B |
| Net income | ₩22B | ₩30B | ₩13B | ₩12B | ₩9.5B |
| Net income to shareholders | ₩22B | ₩30B | ₩13B | ₩12B | ₩9.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩268B | ₩228B | ₩120B | ₩114B | ₩99B |
| Current assets | ₩46B | ₩43B | ₩48B | ₩46B | ₩41B |
| Cash and equivalents | ₩2.2B | ₩1.8B | ₩5.1B | ₩754M | ₩12B |
| Total liabilities | ₩108B | ₩108B | ₩30B | ₩37B | ₩33B |
| Current liabilities | ₩88B | ₩20B | ₩25B | ₩31B | ₩27B |
| Borrowings | ₩1.1B | ₩79B | ₩7.5B | ₩9.9B | ₩8.7B |
| Total equity | ₩160B | ₩120B | ₩90B | ₩78B | ₩65B |
| Shareholders' equity | ₩160B | ₩120B | ₩90B | ₩78B | ₩65B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩1.5B | ₩13B | ₩8.5B | ₩7.4B | ₩2B |
| Capital spending | ₩1.6B | ₩550M | ₩682M | ₩3.2B | ₩2.5B |
| Free cash flow | −₩179M | ₩12B | ₩7.9B | ₩4.2B | −₩546M |
| Dividends paid | ₩1.7B | ₩1.6B | ₩1.6B | ₩1.1B | ₩1.1B |
Consolidated where available. Amounts in won.
Also known as: JIN Yang Pharmaceutical / 진양제약 / 007370 / KRX:007370
Source: KRX statistical information